Valle William 4

What Happened
William Valle, a director of TriSalus Life Sciences (TLSI), received equity awards on May 14, 2026 totaling 109,157 shares: 28,201 RSUs, 24,553 RSUs (retainer elected in lieu of cash), and 56,403 shares as a derivative option award. All grants were recorded at $0.00 (compensation awards rather than open-market purchases or sales).

Key Details

• Transaction date: May 14, 2026; Form 4 filed May 15, 2026 (timely filing).
• Awards: 28,201 RSUs (F1), 24,553 Retainer RSUs (F2), 56,403-share option/derivative award (F3). Total reported = 109,157 shares. Price reported = $0.00.
• Vesting: F1 RSUs vest in full on the one-year anniversary (May 14, 2027). F2 Retainer RSUs vest quarterly in equal one‑third installments through the remainder of 2026 (subject to continued service). F3 option shares fully vest on the one‑year anniversary (May 14, 2027).
• Shares owned after the transaction: not specified in the reported Form 4.
• Filing status: timely (no lateness indicated).

Context
These were compensation grants (RSUs and an option) to a non-employee director, replacing or supplementing cash retainer pay for part of the award. Such awards are routine director compensation and do not represent an open-market purchase or sale; they vest over time and do not imply immediate sale or exercise.